Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2024 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver...
June 12, 2024 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...
April 30, 2024 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)

CAMBRIDGE, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
January 08, 2024 08:00 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones

Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans Selection of...
December 06, 2023 16:08 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Announces Initiation of Dosing in Clinical Trial Evaluating First-Ever RNA Editing Candidate, WVE-006, in Alpha-1 Antitrypsin Deficiency
March 27, 2023 02:27 ET | Source: Market.Us

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size to Hit Around USD 2,517 Mn by 2032

New York, March 27, 2023 (GLOBE NEWSWIRE) -- The global alpha-1 antitrypsin deficiency augmentation therapy market size accounted for USD 1,413 million in 2022 and growth is estimated to accelerate...
January 09, 2023 06:30 ET | Source: Future Market Insights Global and Consulting Pvt. Ltd.

Global Alpha-1 Antitrypsin Deficiency (A1ATD) Treatment Market to Reach US$ 10 Billion by 2033; Growing at an Impressive 12.8% CAGR – Future Market Insights, Inc.

NEWARK, Del, Jan. 09, 2023 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global Alpha-1 Antitrypsin Deficiency market to augment at a 12.8% CAGR from 2023 to 2033. By the end of...
August 12, 2021 20:00 ET | Source: DelveInsight Business Research LLP

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies and Novel Therapeutic Assessment

Los Angeles, USA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Alpha-1 Antitrypsin Deficiency Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies and Novel...